Zacks Investment Research upgraded Curis, Inc. (NASDAQ:CRIS) to Hold in a report released today.
- Updated: September 19, 2016
Zacks Investment Research has upgraded Curis, Inc.(NASDAQ:CRIS) to Hold in a statement released on Monday September 19 2016.
Boasting a price of $2.02, Curis, Inc. (NASDAQ:CRIS) traded 4.46% higher on the day. With the last stock price up 21.74% from the two hundred day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. Curis, Inc. has logged a 50-day average of $1.78 and 200-day average of $1.73. Trade volume was was up over the average, with 1,494,886 shares of CRIS changing hands over the typical 387,939 shares.
Recent Performance Graph:
Curis, Inc. has a 52 week low of $1.25 and a 52 week high of $3.18. CRIS’s total market value is currently $0.0.
In addition to Zacks Investment Research reporting it’s stock price target, a total of 5 firms have reported on the stock. The one year target stock price is $5.60 with two firms rating the stock a strong buy, four firms rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and lastly 0 brokeragesrating the stock as sell.
General Company Details For Curis, Inc. (NASDAQ:CRIS)
Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, and which is an oral HSP90 inhibitor for the development in advanced lung cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.